SPLASH BEVERAGE GROUP INC (SBEV)
AMEXConsumer StaplesBeverages - Wineries & DistilleriesSnapshot 2026-09-04
$0.31-25.92%
Close 2026-08-28 · 1-day change
AMEXConsumer StaplesBeverages - Wineries & DistilleriesSnapshot 2026-09-04
QuarterlyIQ Insights · SBEV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 386.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 2 industry peers · Company calendar date is not available
SBEV — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-08-28
Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master Fund, LP as purchaser (the “ELOC Agreement”) for total gross proceeds of $107,610.62. The ELOC Agreement was previously disclosed in the Company’s Current Report on Form 8-K filed on September 25, 2025. To the extent such sales…
Why it matters: This decision will decide if the company keeps its NYSE listing. A good outcome helps ongoing plans.
Supportive ifNYSE American accepts the compliance plan. The company can keep trading.
Worry ifNYSE American rejects the compliance plan. This may lead to delisting.
Why it matters: New partnerships can help growth and support the company's plans in cannabinoid health.
Supportive ifNews of new partnerships that increase CannEpil's market reach or skills.
Worry ifNo new partnerships show a lack of growth.
Why it matters: The company is investing in Avicanna. This may show a new focus and new partners.
Supportive ifThe company is making new investments or partnerships. These will help its strategy.
Worry ifThere are no new investments or bad news about the Avicanna partnership.
Why it matters: Updates on the CannEpil veterinary program could signal growth in a new market segment. Success here may enhance revenue.
Supportive ifLook for news about FDA progress or partnerships for CannEpil in pet care.
Worry ifWatch for delays in CannEpil's development for pets.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$558 on $10,000 · ±5.6% | How much price usually moves either way. |
| Bad day | $1,603 loss on $10,000 · 16.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,695 loss on $10,000 · 97.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The CannEpil license could expand the product line and drive growth. Success here is key.
Supportive ifThe company announces the launch of CannEpil in key markets.
Worry ifThe company delays the launch of CannEpil or fails to provide updates.
Why it matters: The company faces a serious risk of delisting due to equity non-compliance. Progress here is critical.
Worry ifThe company sends a compliance plan to NYSE. It meets the $6 million equity requirement.
Less concerning ifThe company fails to submit a compliance plan or receives further notices from NYSE.
Why it matters: CannEpil licensing revenue shows it entered the market well. It supports the move to cannabinoid health.
Supportive ifLook for news about first revenue from CannEpil licensing deals.
Worry ifNo revenue from CannEpil licensing will be in the next financial report.
Why it matters: This report will show financial performance and compliance progress. Strong results may boost investor sentiment.
Supportive ifEarnings report shows revenue growth or positive cash flow.
Worry ifEarnings report shows ongoing losses or worse financial metrics.
Why it matters: The reverse stock split is crucial for compliance with NYSE minimum price requirements. It may stabilize share price.
Supportive ifReverse stock split effective after market closes on July 24, 2026.
Worry ifFailure to execute the reverse stock split as planned.
Why it matters: If the FDA approves, it will show the company is moving to cannabinoid health products.
Supportive ifA press release confirms CannEpil's Z application was sent to the FDA.
Worry ifNo news about the CannEpil submission by the end of September 2026.
Why it matters: Approval will help the company keep its NYSE listing and avoid delisting risks.
Supportive ifConfirmation from NYSE that the compliance plan is accepted.
Worry ifNotice of delisting or not meeting rules by January 29, 2027.
Why it matters: New partnerships could boost growth and improve operations in the cannabinoid field.
Supportive ifLook for news about new partnerships in the cannabinoid wellness field.
Worry ifNo new partnerships announced by the end of 2026.